Hyderabad, June 12 -- Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and manufacturing, announced on Thursday that it has partnered with GSK plc, a global biopharma company, for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3.
Shigellosis is an acute human inflammatory disease of the large intestine caused by Gram-negative Shigella. Watery diarrhea, fever, abdominal cramps and pain, and bloody and mucus-filled stools characterize it.
The agreement marks a critical step in the advancement of this promising vaccine, targeting Shigellosis-a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries...